It has been reported that CD133+ glioma cells were sufficient to develop xenografted tumors in vivo that recapitulated the heterogeneity of the original tumor, and thus is considered as GSCs (Singh et al., 2004; Beier et al., 2007). The gene discussed is PROM1; the disease is glioma.